Astria Therapeutics, Inc. (NASDAQ:ATXS) Short Interest Update

Astria Therapeutics, Inc. (NASDAQ:ATXS) was the recipient of a large decline in short interest in the month of September. As of September 30th, there was short interest totalling 3,470,000 shares, a decline of 9.2% from the September 15th total of 3,820,000 shares. Approximately 7.3% of the company’s shares are sold short. Based on an average daily trading volume, of 381,000 shares, the days-to-cover ratio is presently 9.1 days.

Astria Therapeutics Stock Performance

Shares of Astria Therapeutics stock opened at $11.49 on Wednesday. The business has a 50-day simple moving average of $11.35 and a 200-day simple moving average of $10.50. Astria Therapeutics has a one year low of $4.26 and a one year high of $16.90. The company has a market cap of $630.95 million, a PE ratio of -4.95 and a beta of 0.71.

Astria Therapeutics (NASDAQ:ATXS) last posted its quarterly earnings results on Monday, August 12th. The biotechnology company reported ($0.43) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.05). On average, sell-side analysts predict that Astria Therapeutics will post -1.72 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on ATXS. Evercore ISI raised Astria Therapeutics to a “strong-buy” rating in a research note on Wednesday, August 14th. Wedbush reissued an “outperform” rating and set a $22.00 price target on shares of Astria Therapeutics in a research report on Tuesday, August 13th. Oppenheimer lifted their price objective on shares of Astria Therapeutics from $25.00 to $26.00 and gave the company an “outperform” rating in a report on Tuesday, August 13th. HC Wainwright reiterated a “buy” rating and set a $16.00 target price on shares of Astria Therapeutics in a report on Friday, September 27th. Finally, TD Cowen assumed coverage on shares of Astria Therapeutics in a research report on Monday, July 29th. They issued a “buy” rating and a $35.00 price target for the company. Five research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $25.20.

Hedge Funds Weigh In On Astria Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of ATXS. Quest Partners LLC lifted its holdings in Astria Therapeutics by 3,310.6% during the 2nd quarter. Quest Partners LLC now owns 3,206 shares of the biotechnology company’s stock worth $29,000 after buying an additional 3,112 shares during the last quarter. Ameritas Investment Partners Inc. raised its position in shares of Astria Therapeutics by 135.6% during the 1st quarter. Ameritas Investment Partners Inc. now owns 4,971 shares of the biotechnology company’s stock worth $70,000 after acquiring an additional 2,861 shares in the last quarter. SG Americas Securities LLC purchased a new stake in Astria Therapeutics during the third quarter worth approximately $155,000. Hsbc Holdings PLC acquired a new position in Astria Therapeutics in the second quarter valued at approximately $171,000. Finally, Price T Rowe Associates Inc. MD purchased a new position in Astria Therapeutics in the first quarter valued at approximately $200,000. Institutional investors and hedge funds own 98.98% of the company’s stock.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.